Trial Profile
Stereotactic Ablative Body Radiotherapy (SABR) Combined With Immunotherapy (L19-IL2) in Stage IV NSCLC Patients, ImmunoSABR: a Multicentre, Randomised Controlled Open-label Phase II Trial
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 31 Jan 2024
Price :
$35
*
At a glance
- Drugs Bifikafusp alfa (Primary) ; Antineoplastics
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms IMMUNOSABR2
- 26 Jan 2024 This trail has been discontinued in France, according to European Clinical Trials Database record.
- 05 Jun 2023 Planned End Date changed from 1 Dec 2024 to 31 Dec 2025.
- 08 Jul 2022 Planned End Date changed from 1 Dec 2023 to 1 Dec 2024.